Cancer Clinical Trials Office Blog

News & Updates from the CCTO

Frontiers in Cancer Clinical Translation Special Panel Discussion: COVID and Cancer – December 8, 2020

-

The “Frontiers in Cancer Clinical Translation” Seminar Series presents a Special Panel Discussion on Tuesday, December 8, 2020 at 8AM:

Title “COVID and Cancer: Changes in Cancer Practice, Patient Outcomes, and Lessons from Cancer in the Development of anti-SARS-CoV-2 Vaccines“

Panelists:

Anjali Sibley, moderator (Medical Director, Hematology/Medical Oncology, Stanford Medicine Cancer Center in Emeryville)

Julie Wu, Fellow (Postdoctoral Fellow, Oncology)
Sumit Shah, Clinical Assistant Professor of Medicine (Oncology)

Ron Levy, Robert K. and Helen K. Summy Professor in the School of Medicine (Oncology)

Heather Wakelee, Professor of Medicine (Oncology), Chief, Division of Oncology

Date: Tuesday, December 8, 2020, 8AM-9AM

Zoom Link

Topic: Frontiers in Cancer Clinical Translation

Time: Dec 8, 2020 08:00 AM Pacific Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android: https://stanford.zoom.us/j/96871321378?pwd=TGtuUGhucFFQSlBTTFZmY1VhT0pKZz09

Password: 470026

Or iPhone one-tap (US Toll): +18333021536,,96871321378# or +16507249799,,96871321378#

Or Telephone:

Dial: +1 650 724 9799 (US, Canada, Caribbean Toll) or +1 833 302 1536 (US, Canada, Caribbean Toll Free)

Meeting ID: 968 7132 1378

Password: 470026

International numbers available: https://stanford.zoom.us/u/azqaTL1Oz

Meeting ID: 968 7132 1378

Password: 470026

SIP: 96871321378@zoomcrc.com

Password: 470026

Brentuximab Vedotin Receives FDA Approval for Peripheral T-Cell Lymphoma

-

Seattle Genetics announced FDA approval for Brentuximab Vedotin (Adcetris) in combination with chemotherapy for peripheral T-cell Lymphoma, based on the ECHELON-2 (SGN35-014) study conducted in part at Stanford by the Advani team members. For more information please see the press release.

Congratulations to Jessica, Sipra, Thu and the rest of the team for their contribution to the approval of treatment for this difficult to treat disease.

Larotrectinib Receives FDA Approval

-

The Developmental Therapeutics team is celebrating a new FDA approval based on data generated on the study LOXO-TRK-15002. More than 10% of the overall data leading to the approval of Larotrectinib (Vitrakvi) was generated by Dr. Kummar and her team at Stanford. Many thanks for their hard work on this clinical trial.

Larotrectinib is an oral agent for management of solid tumors with NTRK gene fusions, a rare oncogenic driver found in more than 25 types of cancers, from sarcomas to GI and lung cancers, from breast cancer to melanoma. It is a new alternative treatment for adults and pediatric patients with metastatic or progressive disease, including cases where tumor resection is likely to cause injury or disability. It is the first therapy approved for this type of genomic abnormality, regardless of cancer type. It is also only the second drug approved for a tissue agnostic indication (across tumor histologies).

For more information please see the FDA press release.

Staff Kudo

-

Congratulations to Thu Tran from the Lymphoma team, who was published as a co-author in an article recently published in the NEJM about Dr. Advani’s anti CD-47 study! This article was mentioned last week in the blog and can be read here. Great job, Thu!